c-Kit (D816V)

KIT · Variant type: point · HGVS: p.D816V

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ripretinib	98.7%	1.3%	92.95
2	Pralsetinib	97.7%	2.3%	93.43
3	Nintedanib	96.9%	3.1%	90.23
4	Brigatinib	96.8%	3.2%	82.96
5	Selpercatinib	96.8%	3.2%	96.72
6	Dasatinib	96.1%	3.9%	87.97
7	Fostamatinib	95.8%	4.2%	96.74
8	Pacritinib	95.3%	4.7%	88.64
9	Avapritinib	94.6%	5.4%	97.73
10	Gilteritinib	92.7%	7.3%	88.97
11	Bosutinib	91.0%	9.0%	87.22
12	Mitapivat	86.8%	13.2%	100.00
13	Sunitinib	85.4%	14.6%	91.73
14	Alectinib	84.2%	15.8%	95.49
15	Erdafitinib	83.1%	16.9%	95.71
16	Ponatinib	80.7%	19.3%	78.23
17	Apatinib	80.6%	19.4%	97.73
18	Vandetanib	78.1%	21.9%	95.74
19	Capivasertib	77.8%	22.2%	96.48
20	Fedratinib	77.7%	22.3%	96.21
21	Pazopanib	77.3%	22.7%	97.49
22	Umbralisib	76.7%	23.3%	98.74
23	Tenalisib	62.6%	37.4%	97.98
24	Upadacitinib	61.6%	38.4%	97.98
25	Tivozanib	61.5%	38.5%	92.42

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ripretinib	98.7%	—	—
Pralsetinib	97.7%	—	—
Nintedanib	96.9%	—	—
Brigatinib	96.8%	—	—
Selpercatinib	96.8%	—	—
Dasatinib	96.1%	—	—
Fostamatinib	95.8%	—	—
Pacritinib	95.3%	—	—
Avapritinib	94.6%	—	—
Gilteritinib	92.7%	—	—
Bosutinib	91.0%	—	—
Mitapivat	86.8%	—	—
Sunitinib	85.4%	—	—
Alectinib	84.2%	—	—
Erdafitinib	83.1%	—	—
Ponatinib	80.7%	—	—
Apatinib	80.6%	—	—
Vandetanib	78.1%	—	—
Capivasertib	77.8%	—	—
Fedratinib	77.7%	—	—
Pazopanib	77.3%	—	—
Umbralisib	76.7%	—	—
Tenalisib	62.6%	—	—
Upadacitinib	61.6%	—	—
Tivozanib	61.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.1ms